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minor bleeds is taken into account, and the subsequent
cost consequences over time offset the surgical costs.
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OBJECTIVES: Emergency liver transplantation repre-
sents the only effective and recognized therapy for fulmi-
nant hepatic failure (FHF). However, many patients die
while waiting for a donor liver. Bioartificial liver devices
such as the Extracorporeal Liver Assist Device (ELAD)
could allow for sufficient support until a donor liver be-
comes available or until the patient’s own liver can re-
cover. The objective of this study was to assess the cost-
effectiveness of ELAD in FHF patients.
METHODS: We performed a cost-effectiveness analysis
from a payer perspective using clinical data from 19 pa-
tients who received either ELAD or usual care in a Phase
II randomized clinical trial. A statistically significant im-
provement in bridging to transplant with the use of
ELAD was found, with 67% ELAD patients surviving 30
days, compared to 43% of patients in the usual care
group. A decision-analytic model was used to determine
the incremental cost per additional year of life gained
with ELAD versus usual care. Costs were derived from
liver transplant literature.
RESULTS: The incremental cost per additional year of
life gained for ELAD compared with usual care ranged
from $49,200 to $71,500. Among those patients requir-
ing liver transplant, the cost per additional year of life
gained was $52,600 compared to individuals not receiv-
ing a transplant. The model was sensitive to assumptions
regarding the cost of ELAD and the proportion of pa-
tients successfully bridged to transplant.
CONCLUSIONS: ELAD bioartificial liver device may of-
fer both survival and economic benefits to FHF patients.
ELAD appears to be a reasonable and cost-effective alter-
native to usual care in the treatment of FHF. In addition
to its value as a bridge to transplant, ELAD may offer
even more health and cost benefits as a bridge to recov-
ery. Future studies will continue to examine this effect
across larger populations.
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OBJECTIVE: To perform economic evaluations both of
cost-effectiveness (C/E) and cost-utility (C/U) analysis of
erectile dysfunction treatments, sildenafil and intracav-
ernous alprostadil, depending on whether they are pre-
scribed in primary (PC) or specialized (SC) care.
METHODS: The costs include diagnosis, treatment and
clinical follow-up, have been obtained from Spanish offi-
cial Administration and Hospitals data. The cost of the
treatment was the wholesale price in year 2000. Utility
units were assessed using time trade-off and efficacy rates
obtained from the scientific literature.
RESULTS: The annual costs of the treatments for four
monthly drug administrations, vary between €421,02
(sildenafil in PC); €608,42 (sildenafil in SC) and €715,28
(alprostadil IC) for the first year and €370,89 (sildenafil
PC), €404,67 (sildenafil SC) and €465,92 (alprostadil)
for each of the following years. The C/E and C/U values
lie between €568,18 and €3,465.19, respectively for
sildenafil in PC and €821,07 and €5.007,54 respectively
for sildenafil in PC for the first year of treatment. For al-
prostadil, the values during the first year are €1.027,71
(C/E) and €5.431,5 (C/U). For the following years they
are €500,53 (C/E) and €3053,60 (C/U) for sildenafil in PC,
€546,11 (C/E) and €3330,60 (C/U) for sildenafil in SC
and €669,43 (C/E) and €3537,76 (C/U) for alprostadil.
CONCLUSIONS: Treatment with sildenafil is cheaper
than with alprostadil. Sildenafil has a better pharmaco-
economic profile than alprostadil, both in terms of C/U
and C/E analyses. Sildenafil is the best therapeutic option
in terms of C/E and C/U ratios for the treatment of erec-
tile dysfunction when it is prescribed in primary care.
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OBJECTIVE: To develop a generalizable, responsive and
sensitive self-administered instrument by combining dis-
ease-specific and preference-based approaches in an ED-
specific HRQL instrument.
METHODS: Literature review provided structure for ex-
pert panel discussion. Consensus regarding content pro-
duced eight domains and five levels within each domain
describing a continuum of dysfunction-function. This
content formed the foundation for a preference-based
self-administration HRQL instrument, consisting of two
visual analog scales (VAS). Scale 1 allows the rating of
the patient’s self-state along with three ‘marker’ health
